IP Library › Granted Patent US 10,478,408
Granted Patent B2
US 10,478,408 · App. 15/881,475 · Granted Nov 19, 2019

Combination treatments for opioid crisis

Inventor: Michael Presti (Jacksonville, OR)
A61K31/145A61K31/137A61K31/4468A61K31/485A61P25/04A61P25/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,478,408
App. No.
15/881,475
Granted
Nov 19, 2019
Kind
B2
Abstract

A method of reducing the risk of medication-related overdose, death, or other injury associated with inappropriate consumption of alcohol in conjunction with prescription opioid analgesics, comprising: administering a combination medication having an effective amount of one or more opioid medications, and an effective amount of one or more aldehyde dehydrogenase inhibitors, in order to provide the powerful analgesic effects of the opioid in conjunction with a substance that prevents concomitant alcohol consumption, thereby reducing the risk of alcohol mediated opioid overdose or death. A combination medication, including an effective amount of one or more opioid medications, and an effective amount of one or more aldehyde dehydrogenase inhibitors and a pharmaceutically acceptable carrier.

Claims (24)

1. A method of reducing the chances of alcohol mediated opioid overdose or death during maintenance therapy for management of pain, comprising:

selecting a subject for maintenance therapy for management of pain;

administering a single composition to the subject, comprising:

an effective amount of one or more opioid medications for the management of pain; and

an effective amount of one or more aldehyde dehydrogenase inhibitors sufficient to prevent alcohol consumption, the one or more aldehyde dehydrogenase inhibitors selected from disulfiram, calcium carbimide, coprine, cyanamide, 1-aminocyclopropanol, daidzin, cephalosporins, antidiabetic sulfonyl ureas, metronidazole, ampal, benomyl, citral and active isomers thereof, chloral hydrate, chlorpropamide analogs, (benzoyloxy)[4-chlorophenyl)sulfonyl]carbamic acid 1,1-dimethylethyl ester (NPI-1), 4-chloro-N-ethyl-N-[(propylamino)carbonyl]benzenesulfonamid (API-1), 3-(((3-(4-(methylsulfonamido)phenyl)-4-oxo-4H-chromen-7-yl)oxy)methyl)benzoic acid (CVT-10216), N,N-diethylaminobenzaldehyde (DEAB), gossypol, molinate, nitroglycerin, pargyline, or pharmaceutically acceptable salts thereof, enabling provision of the powerful analgesic effects of the opioid in a manner which prevents concomitant alcohol consumption, thereby reducing the risk of alcohol mediated opioid overdose or death during maintenance therapy for management of pain.

2. The method of claim 1 , wherein the aldehyde dehydrogenase inhibitor is disulfiram, or an pharmaceutically acceptable salts thereof.

3. The method of claim 1 , wherein the aldehyde dehydrogenase inhibitor is disulfiram, or pharmaceutically acceptable salts thereof.

4. The method of claim 1 , wherein the one or more opioid medications is one or more prescription opioid analgesics.

5. The method of claim 1 , wherein the one or more opioid medications comprises one or more of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, sufentanil, tilidine, and tramadol.

6. The method of claim 5 , wherein the one or more opioid medications is morphine, methadone, hydrocodone, oxycodone, hydromorphone, fentanyl, or codeine.

7. The method of claim 6 , wherein the one or more opioid medications consists essentially of one or more of morphine, methadone, hydrocodone, hydromorphone, oxycodone, fentanyl, or codeine.

8. The method of claim 1 , wherein the subject is prescribed one or more opioid medications for the management of chronic pain.

9. The method of claim 1 , wherein the subject is prescribed one or more opioid medications for the management of acute pain.

10. A method of reducing the chances of alcohol mediated opioid overdose or death during maintenance therapy for management of pain, comprising:

selecting a subject for maintenance therapy for management of pain;

administering in a single dose a single combination medication, comprising:

an effective amount of an opioid medication for the management of pain selected from alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, sufentanil, tilidine, and tramadol; and

an effective amount of one or more aldehyde dehydrogenase inhibitors selected from disulfiram, calcium carbimide, coprine, cyanamide, 1-aminocyclopropanol, daidzin, cephalosporins, antidiabetic sulfonyl ureas, metronidazole, ampal, benomyl, citral and active isomers thereof, chloral hydrate, chlorpropamide analogs, (benzoyloxy)[4-chlorophenyl)sulfonyl]carbamic acid 1,1-dimethylethyl ester (NPI-1), 4-chloro-N-ethyl-N-[(propylamino)carbonyl]benzenesulfonamid (API-1), 3-(((3-(4-(methylsulfonamido)phenyl)-4-oxo-4H-chromen-7-yl)oxy)methyl)benzoic acid (CVT-10216), N,N-diethylaminobenzaldehyde (DEAB), gossypol, molinate, nitroglycerin, pargyline, or pharmaceutically acceptable salts thereof, enabling provision of the powerful analgesic effects of the opioid in a manner which prevents concomitant alcohol consumption, thereby reducing the risk of alcohol mediated opioid overdose or death during maintenance therapy for management of chronic pain.

11. The method of claim 10 , wherein the aldehyde dehydrogenase inhibitor is disulfiram, or a pharmaceutically acceptable salts thereof.

12. The method of claim 10 wherein the aldehyde dehydrogenase inhibitor consists essentially of disulfiram, or pharmaceutically acceptable salts thereof.

13. The method of claim 10 , wherein the one or more opioid medications comprises morphine, hydrocodone, oxycodone, hydromorphone, fentanyl, or codeine.

14. The method of claim 13 , wherein the one or more opioid medications consists essentially of one or more of morphine, hydrocodone, hydromorphone, oxycodone, fentanyl, or codeine.

15. The method of claim 10 , wherein the subject is prescribed one or more opioid medications for the management of chronic pain.

16. The method of claim 10 , wherein the subject is prescribed one or more opioid medications for the management of acute pain.

Continuity (1)
Related Publication 20190231719A1 · Aug 1, 2019